Catalysts
QURE Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
QUREuniQure N.V.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum41
- Value38
- Quality42
- Risk resilience31
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 41/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 13.46%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | — | -$0.92 | -$0.88 | +3.9% | $6.17M | $5.2M |
| Jul 29, 2026 | — | -$0.82 | -$1.22 | -48.4% | $5.45M | $5.84M |
| May 5, 2026 | — | -$0.88 | -$0.85 | +3.4% | $5.2M | $3.56M |
| Mar 2, 2026 | — | -$0.93 | -$0.56 | +39.8% | $5.33M | $5.57M |
| Nov 10, 2025 | — | -$0.85 | -$1.38 | -62.4% | $4.84M | $3.7M |
| Jul 29, 2025 | — | -$0.89 | -$0.69 | +22.5% | $4.63M | $5.26M |
| May 9, 2025 | — | -$1.07 | -$0.82 | +23.4% | $5.9M | $1.57M |
| Feb 27, 2025 | — | -$0.60 | -$1.50 | -150.0% | $18.45M | $5.22M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
~ FDA sets PDUFA target action date of May 1, 2027 ~~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatmen...
UniQure Stock Falls 37% After Huntington's Disease Trial Update
Shares of uniQure N.V. (QURE) are falling about 37 percent on Tuesday morning after the company announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington's disease.
Related Links
QURE Catalysts FAQ
What are the next catalysts for QURE stock?
QURE's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move QURE stock?
Upcoming events that could move QURE include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could QURE's next earnings report affect the stock?
QURE's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive QURE stock higher?
QURE could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt QURE stock?
QURE could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.